What is the optimal management for an adult with heart failure with reduced ejection fraction and stage 3–4 chronic kidney disease (eGFR 15–59 mL/min)?

Optimal Management of Heart Failure with Reduced Ejection Fraction and Stage 3–4 Chronic Kidney Disease

Core Pharmacologic Strategy

All four foundational HFrEF medications—SGLT2 inhibitors, beta-blockers, ARNI/ACE inhibitors/ARBs, and mineralocorticoid receptor antagonists—should be initiated and titrated in patients with stage 3–4 CKD (eGFR 15–59 mL/min), as the presence of moderate-to-severe kidney disease does not preclude their use and withholding these therapies substantially increases mortality risk. 1, 2, 3

SGLT2 Inhibitors: First-Line Therapy

• Initiate dapagliflozin 10 mg daily (if eGFR ≥20 mL/min/1.73 m²) or empagliflozin 10 mg daily (if eGFR ≥30 mL/min/1.73 m²) immediately at diagnosis, regardless of diabetes status. SGLT2 inhibitors require no dose titration, do not affect blood pressure or heart rate, and provide rapid benefit within weeks. 1, 2

• SGLT2 inhibitors are unique because they facilitate the use of other HFrEF medications—empagliflozin reduces the need for diuretic intensification and lowers the risk of MRA discontinuation due to hyperkalemia. 1

• A mild, transient eGFR decline (typically 5–10 mL/min) commonly occurs within 2–4 weeks of initiation but does not indicate harm; long-term kidney protection is demonstrated in trials. 1, 3

Beta-Blockers: Universal Benefit Across All CKD Stages

• Start bisoprolol 1.25 mg daily, carvedilol 3.125 mg twice daily, or metoprolol succinate 12.5–25 mg daily, then uptitrate every 2 weeks to target doses (bisoprolol 10 mg, carvedilol 25–50 mg twice daily, metoprolol succinate 200 mg). 1, 2, 3

• Beta-blockers reduce mortality by approximately 30% and hospitalizations by 40% in HFrEF patients with CKD, including those on dialysis. 4, 3

• Only bisoprolol may accumulate in severe renal impairment, but dose reduction is not routinely required—titrate to target dose or maximally tolerated dose based on heart rate and blood pressure response. 2

ARNI/ACE Inhibitors/ARBs: Renin-Angiotensin System Inhibition

• Initiate sacubitril/valsartan 24/26 mg twice daily if eGFR ≥30 mL/min/1.73 m², or start an ACE inhibitor (e.g., enalapril 2.5 mg twice daily, lisinopril 2.5–5 mg daily) if eGFR 15–29 mL/min/1.73 m². 1, 5, 2

• Uptitrate sacubitril/valsartan to 97/103 mg twice daily over 3–6 weeks; uptitrate ACE inhibitors to target doses (enalapril 10 mg twice daily, lisinopril 20–40 mg daily). 1

• Accept a creatinine increase up to 30% or eGFR decrease up to 25% from baseline after initiation or dose escalation—this does not mandate discontinuation. 1

• Check renal function and potassium 1–2 weeks after initiation or dose increase; if creatinine rises >30% or potassium >5.5 mmol/L, reduce the dose by 50% and recheck in 1 week. 1

• Sacubitril/valsartan is contraindicated if eGFR <30 mL/min/1.73 m² per FDA labeling. 5

Mineralocorticoid Receptor Antagonists: Essential Despite Hyperkalemia Risk

• Start spironolactone 12.5 mg daily or every other day (or eplerenone 25 mg daily) if eGFR ≥30 mL/min/1.73 m² and baseline potassium <5.0 mmol/L. 1, 2, 3

• Uptitrate to spironolactone 25–50 mg daily or eplerenone 50 mg daily if potassium remains <5.0 mmol/L after 4 weeks. 2

• MRAs reduce HF hospitalizations and mortality even in CKD stage 3–4, but hyperkalemia risk is substantial—check potassium and creatinine at 1 week, 1 month, then every 3 months. 1, 2, 3

• If potassium rises to 5.5–5.9 mmol/L, reduce MRA dose by 50%; if potassium ≥6.0 mmol/L, discontinue MRA and address contributing factors (dietary potassium, NSAIDs, potassium-sparing diuretics). 1

Diuretic Management

• Use loop diuretics (furosemide, torsemide, bumetanide) at the lowest dose that maintains euvolemia; higher doses are required as eGFR declines. 1

• For eGFR 30–59 mL/min, furosemide 40–80 mg daily is typically adequate; for eGFR 15–29 mL/min, furosemide 80–240 mg daily (or equivalent) is often necessary. 1

• If inadequate diuresis despite high-dose loop diuretics, add a thiazide (e.g., metolazone 2.5–5 mg daily, hydrochlorothiazide 25–50 mg daily) for sequential nephron blockade. 1

• Overdiuresis causes hypotension, worsening renal function, and limits tolerance of ARNI/ACE inhibitors and MRAs—titrate diuretics downward once euvolemia is achieved. 1

Monitoring Strategy

• Check serum creatinine, eGFR, and potassium at baseline, 1–2 weeks after initiating or uptitrating ARNI/ACE inhibitors/ARBs or MRAs, then every 3 months once stable. 1

• More frequent monitoring (every 1–2 weeks) is required during active medication titration or if clinical deterioration occurs. 1

• Natriuretic peptides (BNP, NT-proBNP) are elevated in CKD independent of volume status—interpret cautiously and use serial trends rather than absolute values to guide therapy. 1

• Troponin is chronically elevated in CKD but retains strong prognostic value for myocardial infarction and 30-day mortality. 1

Common Pitfalls and How to Avoid Them

• Do not withhold ARNI/ACE inhibitors/ARBs or MRAs solely because of CKD stage 3–4. Undertreatment due to fear of hyperkalemia or worsening renal function is a major cause of preventable mortality in this population. 1, 2, 3

• Do not discontinue ARNI/ACE inhibitors/ARBs for modest creatinine increases (<30%) or eGFR declines (<25%). These changes reflect hemodynamic effects, not nephrotoxicity, and are acceptable if potassium remains <5.5 mmol/L. 1

• Do not assume all HFrEF medications must reach target doses. In CKD stage 4 (eGFR 15–29 mL/min), lower doses of ARNI/ACE inhibitors and MRAs often provide substantial benefit while minimizing adverse effects. 4, 2

• Do not use diltiazem or verapamil for rate control or blood pressure management in HFrEF with CKD. These nondihydropyridine calcium channel blockers increase HF worsening and hospitalization risk. 1

• Do not add an ARB to the combination of an ACE inhibitor and MRA. Triple RAAS blockade substantially increases hyperkalemia and acute kidney injury risk without additional benefit. 1

Device Therapy Considerations

• Refer for ICD evaluation if LVEF ≤35% despite ≥3 months of optimal medical therapy, NYHA class II–III symptoms, and life expectancy >1 year with good functional status. CKD stage 3–4 does not preclude ICD benefit. 1

• Refer for CRT evaluation if LVEF ≤35%, QRS duration ≥130 ms with LBBB morphology, and NYHA class II–IV symptoms despite optimal medical therapy. CRT reduces death and hospitalizations in HFrEF patients with CKD stage 3. 1, 3

Specialist Referral Indications

• Refer to a heart failure specialist if unable to initiate or uptitrate ≥3 of the four foundational HFrEF medications due to hypotension, hyperkalemia, or worsening renal function. 1

• Refer to nephrology if eGFR declines >30% after ARNI/ACE inhibitor/MRA initiation, potassium persistently >5.5 mmol/L despite dose reduction, or eGFR <20 mL/min/1.73 m² to plan renal replacement therapy. 1, 3

• Combined cardiology-nephrology clinics improve implementation of guideline-directed medical therapy in HFrEF patients with CKD. 3